Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.30 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.30 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290178 | 0.82 | P2RX7 (0.34) | MAP2K3KMT2AP2RX7MEN1 | |
| SCHEMBL31275306 | 0.75 | L3MBTL1 (0.34) | MAP2K3KMT2AIKBKB | |
| SCHEMBL27202091 | 0.75 | IKBKB (0.34) | MAP2K3KMT2AP2RX7MEN1IKBKB | |
| SCHEMBL16346446 | 0.74 | KMT2A (0.36) | MAP2K3KMT2AMEN1IKBKB | |
| SCHEMBL5225727 | 0.73 | — | — | |
| SCHEMBL9017967 | 0.70 | SIRT3 (0.50) | KMT2AMEN1 | |
| SCHEMBL27202064 | 0.70 | CA2 (0.31) | — | |
| SCHEMBL21464721 | 0.70 | BID (0.39) | KMT2AMEN1 | |
| SCHEMBL31275565 | 0.69 | HCRTR1 (0.33) | KMT2A | |
| SCHEMBL3145246 | 0.69 | MAP2K3 (0.44) | MAP2K3KMT2AP2RX7MEN1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | CCNA2 631/4885CDK2 2417/4885CCNA1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.